How are these compounds
scientifically different?
Compare mechanisms, targets, research profiles and pharmacokinetics for up to 4 compounds side by side. This maps what is scientifically known — it does not tell you which compound to choose.
This is a scientific comparison, not a recommendation. It does not answer "which should I take?" — for potential combination-specific considerations, see the Interaction Checker; for regulatory/clinical-development history, see the Research Status Explorer.
Target & Mechanism Comparison
Primary molecular targets for each selected compound, drawn directly from each compound's structured scientific record. Not every compound has a single conventional receptor target — where that's the case, its differentiating mechanism is noted below instead.
← Scroll to see all compounds →
| Target | Tesamorelin | Ipamorelin |
|---|---|---|
| ✓ | — | |
| — | ✓ |
Pathway Map
This is a schematic, not a claim that every step shown has been directly demonstrated for each compound. The receptor immediately after each compound is its direct, structurally-confirmed target; anything shown beyond that receptor represents the broader documented signalling axis for that receptor family in general, not a compound-specific downstream finding.
What These Compounds Share
Key Differences
Compound Detail
Tesamorelin
Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.
Synthetic peptide · Synthetic analogue
Tap a target above for a plain-language explanation.
Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.
View Research Sources (4) →
Supports: mechanism_summary, primary_targets
12-month study, 2 sequential phases (6-month double-blind 2:1 tesamorelin:placebo, then 6-month open extension). VAT decreased 10.9% (tesamorelin) vs 0.6% (placebo) at 6 months (P<0.0001); ~18% reduction with 12 months continuous use.
Supports: research_limitations, human_administration_status
Visceral adipose tissue decreased 15.2% (tesamorelin) vs increased 5.0% (placebo), P<0.001.
Supports: research_limitations, human_administration_status
Open-label Phase 2, randomized 3:2 tesamorelin vs standard of care over 6 months. Trend toward improved neurocognitive performance (P=.060) but between-group difference not significant (P=.673) -- a genuine null result.
Supports: experimental_research
Ipamorelin
Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.
Pentapeptide · 5 amino acids · Synthetic
Tap a target above for a plain-language explanation.
Human terminal half-life reported in human PK/PD research.
View Research Sources (1) →
Reports terminal half-life ~2h, clearance 0.078 L/h/kg, Vss 0.22 L/kg.
Supports: human_half_life
Common Research Comparisons
Frequently studied groupings — not recommendations.
Browse more compounds
5-Amino-1MQ
NNMT inhibitor
BPC-157
Gastric pentadecapeptide
Cagrilintide
Long-acting amylin analogue
CJC-1295
Modified GHRH analogue
DSIP
Neuropeptide
Epithalon
Synthetic tetrapeptide
GHK-Cu
Copper-binding tripeptide
GHRP-2
GH-releasing peptide / GH secretagogue
Glutathione
Endogenous antioxidant tripeptide
HCG
Glycoprotein hormone
IGF-1 LR3
IGF-1 receptor agonist (engineered analogue)
Ipamorelin
GH secretagogue
Kisspeptin-10
Kisspeptin fragment
KPV
α-MSH-derived tripeptide
Melanotan I
α-MSH analogue
Melanotan II
Cyclic melanocortin agonist
MOTS-c
Mitochondrial-derived peptide
NAD+
Cellular redox cofactor
PT-141
Cyclic melanocortin receptor agonist
Retatrutide
Triple receptor agonist
rHGH (Somatropin)
Growth hormone receptor agonist
Selank
Synthetic tuftsin analogue
Semaglutide
GLP-1 receptor agonist
Semax
Synthetic ACTH-fragment analogue
Sermorelin
GHRH fragment analogue
SS-31
Mitochondria-targeting tetrapeptide
Tesamorelin
Stabilised GHRH analogue
Thymosin Alpha-1
Thymic peptide
Thymosin Beta-4 (TB-4)
Thymosin Beta-4
Tirzepatide
Dual incretin receptor agonist